

1 **No association between the *Plasmodium vivax crt-o* MS334 or In9pvcrt**
2 **polymorphisms and chloroquine failure in a clinical cohort from Malaysia**

3

4 Angela Rumaseb¹, Roberto R. Moraes Barros², Juliana M. Sá², Jonathan J. Juliano³, Timothy
5 William^{4,5}, Kamil A. Braima¹, Bridget E. Barber^{1,6}, Nicholas M Anstey^{1,5}, Ric N. Price^{1,7,8}, Matthew
6 J. Grigg^{1,5}, Sarah Auburn^{17,8*}, Jutta Marfurt^{1,9*}

7

8 1. Global and Tropical Health Division, Menzies School of Health Research and Charles
9 Darwin University, Darwin, Northern Territory, Australia

10 2. Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious
11 Diseases, National Institutes of Health, Bethesda, MD 20892, USA

12 3. Division of Infectious Diseases, School of Medicine, University of North Carolina at
13 Chapel Hill, Chapel Hill, NC 27599, USA

14 4. Clinical Research Centre, Queen Elizabeth Hospital, Sabah, Malaysia

15 5. Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research
16 Unit, Kota Kinabalu, Sabah, Malaysia

17 6. QIMR Berghofer Medical Research Institute, Brisbane, Australia

18 7. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
19 University of Oxford, Oxford, United Kingdom

20 8. Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok,
21 Thailand

22 9. College of Medicine and Public Health, Flinders University, Darwin, Northern Territory,
23 Australia

24

25 *These authors contributed equally

26 Correspondence to Associate Professor Sarah Auburn, Sarah.Auburn@menzies.edu.au

27

28 **Keywords**

29 *Plasmodium*, vivax, malaria, chloroquine, antimalarial, drug resistance, molecular marker, *pvcrt-o*,

30 **MedRxiv preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

31 Abstract

32 Increasing reports of resistance to a frontline malaria blood-stage treatment, chloroquine (CQ),
33 raise concerns for the elimination of *Plasmodium vivax*. The absence of an effective molecular
34 marker of CQ resistance in *P. vivax* greatly constrains surveillance of this emerging threat. A
35 recent genetic cross between CQ sensitive (CQS) and CQ resistant (CQR) NIH-1993 strains of
36 *P. vivax* linked a moderate CQR phenotype with two candidate markers in *P. vivax* CQ resistance
37 transporter gene (*pvprt-0*): MS334 and In9*pvprt*. Longer TGAAGH motifs at MS334 were
38 associated with CQ resistance, as were shorter motifs at the In9*pvprt* locus. In this study, high-
39 grade CQR clinical isolates of *P. vivax* from Malaysia were used to investigate the association
40 between the MS334 and In9*pvprt* variants and treatment efficacy. Amongst a total of 49
41 independent monoclonal *P. vivax* isolates assessed, high-quality MS334 and In9*pvprt* sequences
42 could be derived from 30 (61%) and 23 (47%), respectively. Five MS334 and six In9*pvprt* alleles
43 were observed, with allele frequencies ranging from 2 to 76% and 3 to 71%, respectively. None
44 of the clinical isolates had the same variant as the NIH-1993 CQR strain, and none were
45 associated with CQ treatment failure (all $p > 0.05$). Our findings suggest that the *pvprt-0* MS334
46 and In9*pvprt* markers cannot be used universally as markers of CQ treatment efficacy in an area
47 of high-grade CQ resistance. Further studies applying hypothesis-free genome-wide approaches
48 are warranted to identify more effective CQR markers for *P. vivax*.

49 Introduction

50 *Plasmodium vivax* malaria remains an important public health burden affecting the poorest and
51 most vulnerable communities of more than 49 endemic countries (1, 2). Chloroquine (CQ) is still
52 the most widely used antimalarial drug to treat *P. vivax* but increasing reports of chloroquine
53 resistance highlight the importance of surveillance of its clinical efficacy (3). Although
54 surveillance of clinical efficacy is the gold standard for the detection of CQ resistance, challenges
55 in discriminating infections deriving from blood stage failures (recrudescence), new mosquito
56 inoculations (reinfections) and reactivation of dormant liver stages (relapses) confounds robust
57 clinical estimates of CQ resistance (4). Molecular surveillance presents a more accurate and cost-
58 effective strategy to identify drug resistant infections (5). However, the genetic basis of CQ
59 resistance in *P. vivax* remains unclear.

60 Several studies have investigated Single Nucleotide Polymorphisms (SNPs) in orthologues of
61 genes involved in CQ resistance in *P. falciparum*, namely *pvct-0* and *pvmdr1*, but none of these
62 markers have been confirmed to be associated with clinical outcomes following CQ treatment of
63 *P. vivax* (6-9). Other studies have reported an association between *pvct-0* expression levels and *P.*
64 *vivax* CQ resistance (10-13). However, no evidence of association was observed between *pvct-0*
65 expression and *ex vivo* drug susceptibility phenotypes using clinical isolates from Papua Indonesia
66 (14), an area where high rates of clinical failure have been documented following CQ treatment
67 (15).

68 More recently, a genetic cross between *P. vivax* subpopulations differing in susceptibility to CQ
69 in non-human primates identified two new, non-coding *pvct-0* markers associated with *in vivo* CQ
70 sensitivity: a repeat length polymorphism (MS334) and an intron 9 polymorphism (In9*pvct*) (12).
71 The MS334 locus is located approximately 0.6 Kb upstream of the start codon of *pvct-0*; CQ
72 sensitive (CQS) progeny contained 10 TGAAGH motifs, whilst CQ resistant (CQR) progeny
73 carried a longer fragment of 15 TGAAGH motifs. At the In9*pvct* locus, 17 TGAAGH motifs
74 were present in CQS progeny, whereas a shorter fragment comprising 14 TGAAGH motifs were
75 present in CQR progeny.

76 The aim of the current study was to correlate the *pvct-0* MS334 and In9*pvct* markers with clinical
77 outcomes following CQ treatment in patients enrolled into a prospective clinical trial conducted
78 in Sabah, Malaysia (16). In this trial more than 60% of patients had recurrent parasitaemia within
79 28 days of treatment, indicative of high-grade CQ resistance (3, 4, 16).

80 Materials and Methods

81 **Sample Collection and Selection**

82 Clinical isolates of *P. vivax* were collected from a comparative efficacy study of patients with
83 uncomplicated vivax malaria conducted in Sabah, Malaysia, between 2012 and 2014 (Clinical
84 Trials Registration number NCT01708876) (16). Briefly, consenting patients aged ≥ 1 year and
85 weighing >10 kg, presenting with acute, uncomplicated vivax malaria to the study hospitals in
86 Kudat, Kota Marudu and Pitas were recruited into the prospective study. Patients were randomly
87 assigned to either CQ (median total dose of 27.7 mg/kg [range, 25.0–33.0]) or artesunate-
88 mefloquine (AS-MQ) (median 11.0 mg/kg [range, 9.8–12.0] AS and 27.6 mg/kg [range, 24.6–
89 30.0] MQ), and followed for 42 days. Administration of primaquine for radical cure was delayed
90 until 28 days of follow up. All treatment doses of chloroquine were supervised. The primary
91 outcome was the cumulative risk of *P. vivax* parasitaemia by day 28. Blood samples were
92 collected at enrolment and on the day of recurrence for molecular analyses. Monoclonal *P. vivax*
93 isolates collected at enrolment into the CQ treatment were selected for further molecular analysis
94 in the *pvcrt-o* study. Isolates were categorized as CQS if the patient exhibited adequate parasite
95 clearance and no recurrent parasitaemia within 42 days. If patients failed to clear peripheral
96 parasitaemia on blood smear or presented with recurrent *P. vivax* parasitaemia within 42 days
97 after CQ treatment in the presence of a minimum effective plasma concentration of chloroquine
98 and desethylchloroquine (CQ+DCQ) of ≥ 15 ng/mL at Day 7 (corresponding to a whole blood
99 concentration of 100ng/mL) (17), they were defined as CQR (16-18). All patient samples and
100 corresponding clinical data were assigned unique study code identifiers (not identifiable to
101 anyone outside the research group) to protect the identity of the subjects.

102

103 **DNA Extraction, Speciation, and Genotyping**

104 DNA was extracted from 200 μ L whole blood using the QIAamp DNA Blood extraction kit
105 according to the manufacturer's procedures (Qiagen, Germany). *Plasmodium spp.* was confirmed
106 using the multiplex PCR method described by Padley et al. (19). *P. vivax* genotyping data was
107 derived from published data stored in the open access vivaxGEN-MS platform
108 (<https://vivaxgen.menzies.edu.au>) using batch code MYPV-MG and applying the default
109 parameters for genotype calling (20). Briefly, genotyping was performed using capillary
110 electrophoresis at nine short tandem repeat (STR) markers to determine the multiplicity of
111 infection (MOI) as previously described (21).

112

113 *pvcrt-o* Gene Fragment Amplification and Sanger Sequencing

114 The primer sequences and PCR cycling conditions are summarised in **Table 1**. The PCR
115 products were run on 2% agarose gel, stained with SYBR™ Safe DNA Gel Stain (Invitrogen,
116 USA) and visualized using the Molecular Imager Gel Doc XR system (Bio-Rad, USA). PCR
117 amplification of *In9pvcrt* yielded multiple bands and henceforth gel extraction was required prior
118 to sequencing, as conducted on previous experiments. Amplicons were sent to Macrogen Inc
119 (Seoul, South Korea), where PCR product purification by gel extraction was conducted prior to
120 sequencing using the dideoxy termination method and the respective PCR primers.

121

122 **Sequence Analysis**

123 Trimming low-quality ends of the sequences were performed using Mega-X software (Version
124 10.2.5). Post-trimming, manual assembly of contigs and comparison with the gene regions of the
125 CQS reference Sal-1 strain were performed using BioEdit software (Version 7.2.5). Alignments
126 were undertaken with the bioinformatician blinded to the CQ treatment outcomes of the
127 patients. To ensure consistency in assemblies between the genetic cross study (12) and the
128 current study, the NIH-1993-S and NIH-1993-R sequences described in the former study were
129 analysed alongside the Malaysian assemblies.

130

131 **Statistical Analysis**

132 All statistical tests were conducted using in-built functions of R (Version 1.2.5042). Proportions
133 were assessed using the Chi-squared test with Yates' correction and Wilcoxon test was used for
134 non-parametric comparisons. A significance threshold of $p < 0.05$ was used for all statistical
135 comparisons.

136

137 **Ethics**

138 All samples were collected with written informed consent from patient or legal guardian for
139 individuals less than 18 years of age. Ethical approval for the patient sampling and parasite
140 molecular analysis was provided by the Human Research Ethics Committee of the Northern
141 Territory Department of Health and Families (HREC-2010-1431, HREC-2012-1815 and HREC-

142 2010-1396), the National Medical Research Ethics Committee, Ministry of Health, Malaysia
143 (NMMR-10-754-6684, NMRR-12-511-12579).

144

145 **Results**

146 **Summary of patient samples and sequencing data**

147 The filtering process for all samples used in the study is presented in **Figure 1**. Amongst 49
148 clinical samples collected at baseline from patients treated with CQ, high-quality sequences could
149 be derived from independent monoclonal *P. vivax* infections for MS334 in 30 (61%) isolates and
150 *In9pvct* in 23 (47%) isolates. An additional 9 high-quality sequences at MS334 and 3 at *In9pvct*
151 were also derived in paired isolates at baseline and day of recurrence. Details of the clinical
152 characteristics of the patients and assay results of the isolates are presented in **Supplementary**
153 **File 1**. There were no significant differences in age, gender, and baseline parasitaemia between
154 the *pvct-o* study set and all patients treated with CQ in the trial (**Table 2**).

155 Sequencing data on the successfully sequenced and aligned MS334 and *In9pvct* amplicons are
156 deposited in Genbank under accession numbers OP807877 - OP807946. The sequencing pass
157 rates amongst the baseline and recurrent infections were 91% (41/45) for MS334 and 69%
158 (31/45) for *In9pvct*.

159

160 **Summary of MS334 and *In9pvct* variants observed in Malaysia**

161 A summary of the MS334 and *In9pvct* genotype calls is provided in **Table 3**. Five MS334 and six
162 *In9pvct* insertion and deletion (indel) variants were identified amongst the Day 0 and recurrent
163 Malaysian isolates, with allele frequencies ranging from 2% (1/41) to 76% (31/41) and 3%
164 (1/31) to 71% (22/31), respectively. Representative sequences of the 5 MS334 and 6 *In9pvct*
165 indels observed in Malaysia, as well as the NIH-1993-R and NIH-1993-S strains, aligned against
166 the Sal-1 reference strain, are provided in **Supplementary Files 2 and 3**.

167 At the MS334 locus, longer TGAAGH motifs were associated with CQR in the NIH-1993-R×S
168 strains (12). The NIH-1993-R type (inferred CQR type) MS334 allele comprising the 15
169 TGAAGH motifs was not observed in Malaysia, and all variants at this locus exhibited shorter
170 motif lengths, ranging from 8-11 motifs. Most clinical isolates also contained motifs shorter than
171 the NIH-1993-S (10 motifs) type.

172 At the *In9pvct* locus, shorter TGAAGH motifs were associated with CQR in the NIH-1993
173 strains (12). The NIH-1993-R type *In9pvct* allele comprising 14 TGAAGH motifs was not
174 observed in the clinical isolates from Malaysia, but motif lengths ranging from 7-17 were
175 observed. Most infections contained 10 TGAAGH motifs (22/31; 71%), which is shorter than
176 both the NIH-1993-R (14 motifs) and NIH-1993-S (17 motifs) types. The distribution of the
177 different TGAAGH (TGAAGC, TGAAGA, TGAAGT) motif lengths observed in clinical CQS,
178 CQR and recurrent isolates are summarised in **Figure 2**.

179

180 **Assessment of MS334 and *In9pvct* association with CQ treatment outcome**

181 There was no statistically significant difference in the proportion of any of the five MS334 or six
182 *In9pvct* alleles (all $p > 0.05$) between CQS and CQR clinical isolates; **Table 3**. Although none of
183 the clinical isolates carried the exact motifs of the NIH-1993-R strains at the MS334 and *In9pvct*
184 loci, the Malaysian MS334 variant types 4 and 5, and *In9pvct* variant types 3, 4 and 5 possessed
185 fragments of the NIH-1993-R indels (**Supplementary Files 2 and 3**). However, there was no
186 significant difference in the proportion of the combined MS334 variants 4 and 5 or combined
187 *In9pvct* variants 3, 4 and 5 between the CQS and CQR isolates as summarised in **Table 4**.

188 Further assessment of the MS334 and *In9pvct* variants was undertaken in paired isolates at
189 baseline and the day of recurrent parasitaemia. Seven of the 9 pairs successfully sequenced at
190 MS334 and all 3 pairs sequenced at *In9pvct* exhibited the same alleles at both time points (**Table**
191 **5**). In the two pairs exhibiting allelic differences at MS334 (MV019 and TK026 pairs), the
192 changes in variants pre- and post-treatment were not consistent. One pair possessed a longer
193 allele at baseline, and the other pair possessed a longer allele at recurrence. Analysis of
194 microsatellite-based genotyping data in two paired isolates revealed evidence of polyclonal
195 infection at recurrence but not at baseline (**Table 6**).

196

197 **Discussion**

198 The involvement of *pvct-o* in conferring CQ resistance in *P. vivax* has been investigated in several
199 studies over the past two decades but remains contentious (8, 10-14, 22). A recent study using a
200 genetic cross between CQS and moderate (surviving paediatric CQ doses) CQR parasite
201 subpopulations of the NIH-1993-S×R strain linked *pvct-o* transcription to CQ resistance and two
202 candidate markers in the gene region (MS334 and *In9pvct*)(12). Our study provides the first

203 investigation of the MS334 and In9*pvrt* variants using samples from a CQ clinical efficacy trial
204 (16). Using patient isolates from a clinical trial of CQ efficacy on *P. vivax* undertaken in Sabah,
205 Malaysia, a region with high-grade CQR during the sample collection period and at a time of
206 residual vivax endemicity, we found that neither MS334 nor In9*pvrt* could predict the clinical
207 outcome following CQ treatment.

208 The genetic cross conducted by Sá and colleagues identified variable TGAAGH motif lengths at
209 MS334 and In9*pvrt* as markers of *in vivo* CQ efficacy (in an *Aotus* host) in CQS and CQR
210 progeny, and that CQR progeny had increased expression of *pvrt-o* (12). However, it is unclear
211 whether either of these indels has a causative role in determining the response to CQ through
212 increased *pvrt-o* expression or other mechanisms. Interestingly, a study of gene expression
213 across lifecycle stages in *P. vivax* isolates from Cambodia showed that *pvrt-o* has multiple
214 potential protein isoforms due to the retention of intron 9 that predicted an early stop codon
215 (23). Another study, conducted on clinical isolates from Thailand and Indonesia, identified an
216 AAG trinucleotide insertion in the *pvrt-o* exon 1 encoding an extra lysine, associated with
217 reduced CQ IC₅₀s, although the insertion was observed predominantly in Thai isolates (76%)
218 rather than Indonesian isolates (2.2%); the study was potentially confounded by population
219 structure effects (7). TGAAGH motifs have been shown to regulate gene expression in
220 *Arabidopsis*, but there is currently no knowledge regarding their role in *Plasmodium* (24, 25). In
221 Malaysia, we observed a wide variety of TGAAGH motif lengths in both MS334 and In9*pvrt*
222 amongst CQS and CQR isolates, with no evidence of a correlation between motif length and
223 clinical outcome following treatment with CQ. For example, the Malaysian CQR isolate TV005
224 possessed the shortest TGAAGH motif lengths in both gene regions, while one CQR isolate
225 collected at recurrence, MK2079, possessed the longest motif lengths in both gene regions.

226 Although increased *pvrt-o* expression has been associated with CQ resistance in several studies
227 (10-12), this pattern has not been replicated in clinical datasets of populations with high-grade
228 CQ resistance. Study of clinical *P. vivax* isolates from Papua, Indonesia, an area of high-grade CQ
229 resistance, found no evidence of association between *pvrt-o* expression and *ex vivo* CQ
230 susceptibility (14). Furthermore, although a population genomic study using phenotype-free
231 methods to detect selective sweeps identified a weak signal of selection in the vicinity of *pvrt-o* in
232 an Ethiopian population, this signal was not identified in similar studies conducted in either
233 Malaysia or Papua, Indonesia, where high grade CQ resistance is present (26-28). It is possible
234 that different CQ resistance mechanisms are involved in different *P. vivax* populations.
235 Alternatively, the CQ resistance mechanism may not be heritable, in which case studies applying

236 population genomic approaches to detect sweeps or association methods using pre-treatment
237 clinical isolates may fail to identify a signal.

238 In the current study, we analysed paired isolates collected at baseline and again on recurrence to
239 explore any changes in the TGAAGH motif lengths after drug exposure. Although the sample
240 size was limited, there was no evidence of an association between MS334 or In9*pvct* motif length
241 and CQ resistance. Six paired isolates had different MS334 motif lengths pre and post treatment,
242 however the direction of change (i.e., increase versus decrease in motif length) was inconsistent.
243 Microsatellite-based genotyping data confirmed that the post treatment isolates were the same
244 strains as those present at pre-treatment, except for two pairs, MV019/MV1019 and
245 TK026/TK1026; in these pairs, the isolate at baseline was monoclonal, but the isolates at
246 recurrence comprised at least two strains. It's plausible that a polyclonal infection was present at
247 both baseline and recurrence, but a minor CQR strain was only detected at recurrence following
248 preferential growth under selective drug pressure. Malaysia is in the pre-elimination stage at the
249 time of the trial, with intense drug pressure resulting in *P. vivax* population bottlenecks, and
250 thus *P. vivax* CQR strains could be present and circulating in the population as the last remaining
251 parasites (26). CQ was the first-line treatment throughout the study period and in view of its very
252 poor efficacy, in 2016 national antimalarial policy was changed to recommend artemisinin
253 combination therapies for the treatment of *P. vivax*.

254 Our study has several limitations. The extensive sequence complexity in the MS334 and In9*pvct*
255 regions, and the high diversity of variants observed in the Malaysian population imposed
256 challenges in sequence alignment and variant calling. To overcome these challenges, we confined
257 our study to high quality monoclonal infections and two independent investigators, both blinded
258 to the sample's CQ sensitivity status, analysed the molecular assemblies. We were unable to rule
259 out the potential impact of host or other parasitological factors that might impact CQ treatment
260 outcome in the Malaysian study. All patients treated with CQ in our study had observed
261 administration with correct dosage based on body weight and confirmed therapeutic plasma CQ
262 concentrations at day 7 (16). At the time of recurrence, 9 of 20 patients assessed in the original
263 study had plasma CQ + DCQ concentrations in excess of 15 ng/mL (range, 19.7–to 120.5),
264 demonstrating parasite growth in the presence of adequate drug concentrations (16). By
265 definition, these parasites were CQR. Furthermore, the risk of recurrence by day 28 exceeded
266 60%, far higher than that expected under the conditions of a clinical trial (3). Our study was also
267 limited by small sample size, and despite the near-equal proportions of the two treatment
268 outcome groups, there was no trend in our findings.

269 In summary, our study found that the MS334 and In9^{pvrt} markers were not effective predictors
270 of clinical outcome following CQ treatment of patients with *P. vivax* malaria in Malaysia. Further
271 studies exploring the mechanism of *P. vivax* CQ resistance and the identification of molecular
272 markers using candidate-free genome-wide approaches are warranted.

273

274 **Acknowledgements**

275 We thank the participants in this study; the Malaysian clinical and laboratory research staff; the
276 Director-General of Health, Malaysia; Kim Piera and Ammar Aziz for conducting the polymerase
277 chain reaction for species diagnosis; and Irene Handayuni for conducting the microsatellite
278 genotyping. The study was funded by the National Health and Medical Research Council
279 (NHMRC) Australia Ideas Grant (APP2001083) awarded to SA, program Grant 1037304, project
280 grant 1045156, and a Senior Principal Research Fellowship to NMA (1135820)], Malaysian
281 Ministry of Health (grant BP00500420), and the AusAID Asia-Pacific Malaria Elimination
282 Network (grant 108-07). The work was also supported by the Australian Centre for Research
283 Excellence on Malaria Elimination (ACREME), funded by the National Health and Medical
284 Research Council of Australia (APP1134989).

285


286 **References**

- 287 1. Auburn S, Cheng Q, Marfurt J, Price RN. The changing epidemiology of *Plasmodium*
288 *vivax*: Insights from conventional and novel surveillance tools. *PLoS Med*. 2021;18(4):e1003560.
- 289 2. WHO. World Malaria Report 2021. Organization WH; 2021.
- 290 3. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of
291 chloroquine-resistant *Plasmodium vivax*: a systematic review and meta-analysis. *Lancet Infect Dis*.
292 2014;14(10):982-91.
- 293 4. Price RN, Auburn S, Marfurt J, Cheng Q. Phenotypic and genotypic characterisation of
294 drug-resistant *Plasmodium vivax*. *Trends Parasitol*. 2012;28(11):522-9.
- 295 5. Jacob CG, Thuy-Nhien N, Mayxay M, Maude RJ, Quang HH, Hongvanthong B, et al.
296 Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control
297 and elimination. *Elife*. 2021;10.
- 298 6. Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, et al.
299 Identification of the *Plasmodium vivax* mdr-like gene (*pvmdr1*) and analysis of single-nucleotide
300 polymorphisms among isolates from different areas of endemicity. *J Infect Dis*. 2005;191(2):272-
301 7.
- 302 7. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, et al.
303 Chloroquine resistant *Plasmodium vivax*: in vitro characterisation and association with molecular
304 polymorphisms. *PLoS One*. 2007;2(10):e1089.
- 305 8. Orjuela-Sanchez P, de Santana Filho FS, Machado-Lima A, Chehuan YF, Costa MR,
306 Alecrim M, et al. Analysis of single-nucleotide polymorphisms in the *crt-o* and *mdr1* genes of

- 307 Plasmodium vivax among chloroquine-resistant isolates from the Brazilian Amazon region.
308 Antimicrob Agents Chemother. 2009;53(8):3561-4.
- 309 9. Sá JM, Nomura T, Neves J, Baird JK, Wellem's TE, del Portillo HA. Plasmodium vivax:
310 allele variants of the *mdr1* gene do not associate with chloroquine resistance among isolates from
311 Brazil, Papua, and monkey-adapted strains. *Exp Parasitol*. 2005;109(4):256-9.
- 312 10. Fernandez-Becerra C, Pinazo MJ, Gonzalez A, Alonso PL, del Portillo HA, Gascon J.
313 Increased expression levels of the *pvcr-t-o* and *pvm-dr1* genes in a patient with severe Plasmodium
314 vivax malaria. *Malar J*. 2009;8:55.
- 315 11. Melo GC, Monteiro WM, Siqueira AM, Silva SR, Magalhaes BM, Alencar AC, et al.
316 Expression levels of *pvcr-t-o* and *pvm-dr-1* are associated with chloroquine resistance and severe
317 Plasmodium vivax malaria in patients of the Brazilian Amazon. *PLoS One*. 2014;9(8):e105922.
- 318 12. Sa JM, Kaslow SR, Moraes Barros RR, Brazeau NF, Parobek CM, Tao D, et al.
319 Plasmodium vivax chloroquine resistance links to *pvcr-t* transcription in a genetic cross. *Nat*
320 *Commun*. 2019;10(1):4300.
- 321 13. Sa JM, Yamamoto MM, Fernandez-Becerra C, de Azevedo MF, Papakrivos J, Naude B, et
322 al. Expression and function of *pvcr-t-o*, a Plasmodium vivax ortholog of *pfcr-t*, in Plasmodium
323 falciparum and Dictyostelium discoideum. *Mol Biochem Parasitol*. 2006;150(2):219-28.
- 324 14. Pava Z, Handayani I, Wirjanata G, To S, Trianty L, Noviyanti R, et al. Expression of
325 Plasmodium vivax *crt-o* Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility.
326 *Antimicrob Agents Chemother*. 2016;60(1):361-7.
- 327 15. Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, et al.
328 Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine
329 and sulfadoxine-pyrimethamine in southern Papua, Indonesia. *Trans R Soc Trop Med Hyg*.
330 2007;101(4):351-9.
- 331 16. Grigg MJ, William T, Menon J, Barber BE, Wilkes CS, Rajahram GS, et al. Efficacy of
332 Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An
333 Open-label, Randomized, Controlled Trial. *Clin Infect Dis*. 2016;62(11):1403-11.
- 334 17. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, et al. Diagnosis of
335 resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine
336 levels. *Am J Trop Med Hyg*. 1997;56(6):621-6.
- 337 18. WHO. Methods for surveillance of antimalarial drug efficacy. 2009.
- 338 19. Padley D, Moody AH, Chiodini PL, Saldanha J. Use of a rapid, single-round, multiplex
339 PCR to detect malarial parasites and identify the species present. *Ann Trop Med Parasitol*.
340 2003;97(2):131-7.
- 341 20. Trimarsanto H, Benavente ED, Noviyanti R, Utami RA, Trianty L, Pava Z, et al.
342 VivaxGEN: An open access platform for comparative analysis of short tandem repeat genotyping
343 data in Plasmodium vivax populations. *PLoS Negl Trop Dis*. 2017;11(3):e0005465.
- 344 21. Abdullah NR, Barber BE, William T, Norahmad NA, Satsu UR, Muniandy PK, et al.
345 Plasmodium vivax population structure and transmission dynamics in Sabah Malaysia. *PLoS One*.
346 2013;8(12):e82553.
- 347 22. Silva SR, Almeida ACG, da Silva GAV, Ramasawmy R, Lopes SCP, Siqueira AM, et al.
348 Chloroquine resistance is associated to multi-copy *pvcr-t-o* gene in Plasmodium vivax malaria in
349 the Brazilian Amazon. *Malar J*. 2018;17(1):267.
- 350 23. Kim A, Popovici J, Vantaux A, Samreth R, Bin S, Kim S, et al. Characterization of P. vivax
351 blood stage transcriptomes from field isolates reveals similarities among infections and complex
352 gene isoforms. *Sci Rep*. 2017;7(1):7761.
- 353 24. Pertea M, Mount SM, Salzberg SL. A computational survey of candidate exonic splicing
354 enhancer motifs in the model plant Arabidopsis thaliana. *BMC Bioinformatics*. 2007;8:159.
- 355 25. Ho LH, Giraud E, Uggalla V, Lister R, Clifton R, Glen A, et al. Identification of regulatory
356 pathways controlling gene expression of stress-responsive mitochondrial proteins in Arabidopsis.
357 *Plant Physiol*. 2008;147(4):1858-73.


- 358 26. Auburn S, Benavente ED, Miotto O, Pearson RD, Amato R, Grigg MJ, et al. Genomic
359 analysis of a pre-elimination Malaysian *Plasmodium vivax* population reveals selective pressures
360 and changing transmission dynamics. *Nat Commun.* 2018;9(1):2585.
- 361 27. Auburn S, Getachew S, Pearson RD, Amato R, Miotto O, Trimarsanto H, et al. Genomic
362 Analysis of *Plasmodium vivax* in Southern Ethiopia Reveals Selective Pressures in Multiple
363 Parasite Mechanisms. *J Infect Dis.* 2019;220(11):1738-49.
- 364 28. Pearson RD, Amato R, Auburn S, Miotto O, Almagro-Garcia J, Amaratunga C, et al.
365 Genomic analysis of local variation and recent evolution in *Plasmodium vivax*. *Nat Genet.*
366 2016;48(8):959-64.
- 367

368 **List of Figures**



369

370 **Figure 1. Flowchart outlining patient sample exclusion.** Abbreviations: *Pv*, *Plasmodium vivax*;
371 CQ, Chloroquine; PCR, polymerase chain reaction; CQS, chloroquine sensitive; CQR, chloroquine
372 resistant; Rec, recurrent infection time point.



373

374 **Figure 2. Dot-boxplots of TGAAGH motif lengths observed in Malaysian isolates.**
375 Abbreviations: CQS, chloroquine sensitive (day 0 infections); CQR, chloroquine resistant (day 0
376 infections); Rec, recurrent infection time point.

377 **List of Tables**

Primer Pair	Primer Sequence (5' – 3')	PCR Cycling Condition
MS334_F	GAAATGTAGATTTAAGTGCA	94°C for 2 min, 40 cycles of (94°C for 30sec, 48°C for 45sec, 72°C for 45sec), 72°C for 5min
MS334_R	TGTCACTTGTCAAATAACA	
Intron9_F	GGTTGGAATGCCAGATG	94°C for 2 min, 40 cycles of (94°C for 30sec, 55°C for 45sec, 72°C for 45sec), 72°C for 5min
Intron 9_R	TCGCAAATGTTGAAAAAGGA	

378

379 **Table 1. Primer sequences and PCR cycling conditions.** PCR = Polymerase Chain Reaction

	Age* N(%)			Males N(%)	Asexual parasitemia ⁱ median (range)
	<5	5-15	>15		
Baseline ^s	1/49 (2.04)	23/49 (46.94)	25/49 (51.02)	33/49 (67.35)	3131 (240-42,521)
Study ⁺	0/34 (0)	17/34 (50)	17/34 (50)	20/34 (58.82)	2933 (408-42,521)
Test statistic (<i>p-value</i>)	$\chi^2=2.218e-31$ (<i>p</i> =1)	$\chi^2=0.003$ (<i>p</i> =0.959)	$\chi^2=0$ (<i>p</i> =1)	$\chi^2=0.316$ (<i>p</i> =0.574)	W= 820 (<i>p</i> =0.908)

380

381 **Table 2. Demographic data of CQ-assigned participants in clinical trial and *pvcrt-o* study**
382 **set.** Symbols: *Age in years, ⁱParasites/ μ L, ^s Participants assigned CQ on baseline, ⁺Participants
383 included in the *pvcrt-o* study set.

Candidate Marker	Variant no.	Indel polymorphism(s)	Positions*	CQS	CQR	X ² § (<i>p</i> -value)	Rec
MS334	1	None	NA	1/17	0/13	6.924e-33 (<i>p</i> =1)	0
	2	16bp insertion	-52	14/17	10/13	3.346e-32 (<i>p</i> =1)	7
	3	16bp insertion	-52	1/17	2/13	0.060	1
		16bp deletion	+43			(<i>p</i> =0.806)	
	4	16bp insertion	-52	1/17	0/13	6.924e-33	0
		16bp insertion ⁱ	+59			(<i>p</i> =1)	
5	32bp insertion	-52	0/17	1/13	0.019	2	
	16bp insertion ⁱ	+59			(<i>p</i> =0.891)		
In9pvcrt	1	None	NA	0/14	0/9	NA	1
	2	41bp deletion	+3121	1/14	0/9	1.584e-31 (<i>p</i> =1)	0
	3	120bp deletion ⁱ	+3135	1/14	1/9	1.259e-32 (<i>p</i> =1)	2
	4	140bp deletion ⁱ	+3135	11/14	7/9	5.980e-31 (<i>p</i> =1)	4
	5	220bp deletion ⁱ	+3095	0/14	1/9	0.052	0
		20bp insertion	+3289			(<i>p</i> =0.820)	
6	180bp deletion	+3095	1/14	0/9	1.584e-31 (<i>p</i> =1)	0	

384

385 **Table 3. Summary of insertion and deletion variants observed in Malaysia.** Abbreviations
386 and symbols: Indels, Insertion and deletion; *Number of base pairs upstream (-) or downstream
387 (+) from the start of *pvcrt-o* in Sal-1 strain (Pv_Sal1_chr01:330,260); § Chi-squared test of CQS vs
388 CQR baseline (i.e., not including the recurrent time point) isolates; ⁱ Part of polymorphisms
389 observed in NIH-1993-R mentioned by (12); CQS, chloroquine sensitive; CQR, chloroquine
390 resistant; Rec, recurrent infection time point. See **Supplementary Files 2 and 3** for sequence
391 details for each variant.

Variant	Coordinate	CQS	CQR	χ^2 (p -value)
MS334; 16bp insertion	Pv_Sal1_chr01:330,319	1/17	1/13	4.016e-31 ($p=1.000$)
In9 <i>pvcr1</i> ; 120-220bp deletion	Pv_Sal1_chr01:333,355	13/14	9/9	1.584e-31 ($p=1.000$)

392

393 **Table 4. Summary of NIH-1993-R-type insertion and deletion polymorphisms observed in**
394 **Malaysia.** Abbreviations and symbols: CQS, chloroquine sensitive; CQR, chloroquine resistant.

Pair	Sample	Insertion at 330,319* (MS334)		Deletion at 333,355* (<i>In9pvcr1</i>)	
		Day 0	Day Rec	Day 0	Day Rec
1	MK079	-	✓	-	X
2	MV010	X	-	-	-
3	MV019	✓	X	-	✓
4	MV021	X	X	✓	✓
5	MV033	X	X	-	✓
6	TK026	X	✓	✓	-
7	TV029	X	X	-	✓
8	TV038	X	X	✓	-
9	TV040	X	X	✓	✓
10	TV048	X	X	✓	✓
11	TV051	X	X	-	-

395


396 **Table 5. Summary of NIH-1993-R-type insertion and deletion polymorphisms observed**
397 **in paired Malaysian isolates.** Abbreviations and symbols: * Positions at chromosome 1 of Sal-
398 1 reference strain; Rec, recurrent infection time point; (-) not amplified; (✓) insertion/deletion is
399 present; (X) insertion/deletion is not present. Infections with day 0 versus recurrence
400 differences are highlighted in **bold**.

Pair	Sample	MS12	pv3.27	msp1f3	MS10	MS5	MS1	MS8	MS16	MS20	MLG*	Indel Mutation Similarities	
												MS334	<i>In9pvct</i>
1	MK079	209	280	258	195	194	237	281	385	201	1	-	-
1	MK2079	209	280	258	195	194	237	281	385	201	1	-	-
2	MV010	206	280	261	180	182	237	263	352	201	2	-	-
2	MV1010	206	280	261	180	182	237	263	352	201	2	-	-
3	MV019	209	280	258	195	182	237	281	385	219	3		
3	MV1019	209	280	258	195/153	182	237	281	385	219	3/4	X	-
4	MV021	209	280	348	195	164	228	281	463	201	5	✓	✓
4	MV1021	209	280	348	195	164	228	281	463	201	5	✓	✓
5	MV033	209	280	255	195	173	237	281	418	201	6	✓	-
5	MV1033	209	280	255	195	173	237	281	418	201	6	✓	-
6	TK026	209	280	255	195	173	237	281	418	201	6	X	-
6	TK1026	209	280	255	195	173/182	237	281	418	201	6/7		-
7	TV029	209	280	255	195	173	237	281	418	201	6	✓	-
7	TV1029	209	280	255	195	173	237	281	418	201	6	✓	-
8	TV038	209	280	255	195	173	237	281	418	201	6	✓	-
8	TV1038	209	280	255	195	173	237	281	418	201	6	✓	-
9	TV040	209	280	255	195	173	237	281	418	201	6	✓	✓
9	TV1040	209	280	255	195	173	237	281	418	201	6	✓	✓
10	TV048	209	280	255	195	173	237	281	418	201	6	✓	✓
10	TV1048	209	280	255	195	173	237	281	418	201	6	✓	✓
11	TV051	209	280	255	195	173	237	281	418	201	6	✓	-
11	TV1051	209	280	255	195	173	237	281	418	201	6	✓	-

401

402 **Table 6. Comparison of microsatellite genotyping data and *pvct-o* MS334 and *In9pvct* markers results in paired Malaysian isolates.**

403 Infections with day 0 versus recurrence differences are highlighted in bold. * Microsatellite-based multi-locus genotype (MLG).



404

405

406 **Supplementary File 2. Aligned sequences from the flanking region of *pvcrt-o* in *P. vivax***

407 **Sal-1 strain, NIH-1993-S, NIH-1993-R and 5 variants of Malaysian MS334 amplicons.**

408 Positions shown are 200bp upstream from the start of *pvcrt-o* in the Sal-1 strain

409 (Pv_Sal1_chr01:330,260). Insertion observed in chloroquine resistant progeny NIH-1993-R is

410 highlighted in red, while region of Malaysian amplicons that contain part of the insertion is

411 highlighted in yellow. V1 to V5 refers to the MS334 allele variant number observed in Malaysian

412 population (see **Table 3**).



413

414 **Supplementary File 3. Aligned sequences of *pvcrt-o* Intron 9 region of *P. vivax* Sal-1 strain,**
 415 **NIH-1993-S, NIH-1993-R and 6 variants of Malaysian isolates.** Positions shown are
 416 approximately 2.8kbp downstream from the start of *pvcrt-o* in Sal-1 strain (Pv_Sal1_chr01:330,260).
 417 Deletion observed in chloroquine resistant progeny NIH-1993-R is highlighted in red, while region
 418 of Malaysian amplicons that contain part of the deletion is highlighted in yellow. V1 to V6 refers
 419 to the *In9pvcrt* allele variant number observed in Malaysian population (see **Table 3**).

420